AffiRis presented very promising Phase I results today of it's a-syn vaccine, PD01A. The safety profile (the real purpose of this phase) was excellent. The non-serious adverse events were evenly distributed among the test groups and control. There were three serious adverse events over the year and none were attributed to the drug.

With regard to preliminary efficacy, the two test groups remained stable throughout the year while the placebo group had deterioration. Even with the small sample sizes the results were significant.

Interesting, not all of the test group subjects actually reacted to the vaccine with a buildup of a-syn antibodies. Only about half of the test group had antibodies in serum samples. When analyzed for only those that had the antibodies, the results much more evident.

The company intends to begin the next study immediately. They are considering adding on locations in the US (they are located in Austria).

Press Release:

http://www.affiris.com/html/en/press...meldungen.html